Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. (Q46152573)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609324%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609324%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609324%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

F Kasteng

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609324%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

J Eriksson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609324%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

K Sennfält

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609324%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

0 references

publication date

24 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609324%20AND%20SRC:MED&resulttype=core&format=json

Acta Psychiatrica Scandinavica

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609324%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

124

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609324%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609324%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

214-225

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609324%20AND%20SRC:MED&resulttype=core&format=json

Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Excess mortality in bipolar and unipolar disorder in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

The metabolic syndrome and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Metabolic side effects of antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Cost-effectiveness of atypical antipsychotic medications versus conventional medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Prediction of Coronary Heart Disease Using Risk Factor Categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Incidence, prevalence, and mortality of diabetes in a large population. A report from the Skaraborg Diabetes Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Age-specific direct healthcare costs attributable to diabetes in a Swedish population: a register-based analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Cost of illness of adult diabetes mellitus underestimated if comorbidity is not considered

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Costs of schizophrenia during 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Annual cost of bipolar disorder to UK society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Utility assessment in patients with mental disorders: validity and discriminative ability of the time trade-off method

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

Measuring health-related quality of life in bipolar disorder: relationship of the EuroQol (EQ-5D) to condition-specific measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

A comparison of individual and social time trade-off values for health states in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2011.01716.X

10.1111/J.1600-0447.2011.01716.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609324%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference